The pharmacokinetics of ceftriaxone were investigated in six healthy mainland Chinese adults (four males and two females). A single 1.0-g dose was administered intravenously or intramuscularly in a two-way crossover design. Plasma and saliva samples were collected on 11 occasions between 0 and 36 h after dosing.
intravenous administration was 0.68 liter/h. The mean Tmax and Cmax after intramuscular injection were 1.4 h and 131 ,ug/ml, respectively. The area under the plasma concentration-time curves after intravenous and intramuscular administrations were 1,507 and 1,493 ,Ig h/ml, respectively. The bioavailability for a 1.0-g intramuscular dose of ceftriaxone was calculated to be 100%. These pharmacokinetic parameters for ceftriaxone in healthy Chinese adults were very similar to those previously reported in the literature. Thus, ceftriaxone may be administered to treat Chinese patients without any major modification in the standard dosing regimen.
Ceftriaxone is a new broad-spectrum parenteral cephalosporin with potent activity against gram-positive and gram-negative bacteria due, in part, to its resistance to various types of 3-lactamase (1) . Its most remarkable feature is a long elimination half-life of 6 to 9 h (8, 13), which makes possible a once-daily dosage schedule.
Studies conducted in Europe and North America have also shown that the bioavailability of intramuscular (i.m.) administration is the same as for the intravenous (i.v.) route (2) (3) (4) (5) , and this, in conjunction with the need for only a daily injection, has the advantages of convenience and cost effectiveness.
It is generally accepted that differences in drug metabolism occur among different races. The underlying cause could be genetic or environmental or both (2, 5, 8) . The higher proportion of fast acetylators among Oriental populations are well known (6, 19) . Comparison studies between Orientals and Caucasians has demonstrated differences between the two races in the disposition of drugs (7, 18) . This might necessitate the use of a separate dosing scheme for patients of different ethnic origins.
The object of this study was to investigate the bioavailability and pharmacokinetics of ceftriaxone in healthy Chinese adults. This provides information on whether the dosing procedure established from experiences based predominantly on Caucasian subjects is applicable to Chinese subjects. At a flow rate of 2.2 ml/min, the retention times for ceftriaxone and diazepam were 4.4 and 3.4 min, respectively. The concentrations of ceftriaxone in unknowns were calculated from peak height ratios, using the internal standard technique.
MATERIALS AND METHODS

Subjects
The lower limit of detection of the assay was 0.5 jig/ml (at a signal/noise ratio of 3). Linear response in the peak height ratio of ceftriaxone and the internal standard was observed at plasma ceftriaxone concentrations of 1 to 500 ,ug/ml. The between-day precision of the method at plasma ceftriaxone concentrations of 10.5, 96.5, and 452.6 p.g/ml was 11.2, 4.6, and 4.1%, respectively (n = 10).
Pharmacokinetic analysis. 
RESULTS
The subjects did not experience any major discomfort during the course of this study. No complications or adverse effects associated with the administration of ceftriaxone were observed. Table 1 shows the mean ceftriaxone concentration in plasma for a 36-h period after a single i.m. or i.v. injection of 1.0 g of ceftriaxone. Data from one subject is presented graphically in Fig. 1 .
After i.m. administration, the mean plasma concentration of ceftriaxone peaked after 1 h. The mean ceftriaxone concentration at 1 h was 125.7 Fxg/ml. After i.v. administration, the plasma concentration of ceftriaxone decreased rapidly during the first 2 h. This was followed by a relatively slow elimination phase.
With either route of administration, a monoexponential elimination phase was observed at 4 to 36 h. During this period, the mean ceftriaxone concentrations after i.m. administration were 17 to 23% higher than those obtained after an i.v. dose. The elimination profiles were similar for the two routes of administration, and a parallel decline in concentration-time curves was observed.
The pharmacokinetic parameters were calculated from plasma concentration data obtained from each volunteer. These are presented in Tables 2 and 3 . For i.m. administration (Table 2) , mean values for time to maximum concentration, maximum concentration, and t1/2P were 1.4, 130.6 ,ug/ml, and 8.2 h, respectively. For i.v. administrations (Table 3) There were no significant differences (P > 0.05) in the mean values obtained for t1/2 and AUC by the two different modes of drug administration. The mean bioavailability of a 1.0-g dose of ceftriaxone after i.m. administration was 1.00 (Table 2) .
Ceftriaxone was not detected in any of the saliva samples. At 2 h after dosage, the ceftriaxone concentrations in plasma were very similar for i.m. and i.v. administration. Apart from a slightly higher plasma concentration after i.m. administration, the two mean plasma concentration-time curves after the second hour could almost be superimposed. Similar observations have been made by previous investigators (2, 4) . Thus, our data provide additional evidence that i.m. administration is an appropriate alternative for i.v. administration of ceftriaxone.
The apparent volume of distribution for ceftriaxone is fairly low compared with that for other cephalosporins. It was found to be 8.5 liters. Ceftriaxone is primarily distributed into vascular fluids, highly vascular organs, and some extravascular fluid (11) . Similar values have been reported by others (6, 8, 9) .
In spite of the low apparent volume of distribution, the half-life of ceftriaxone is long relative to that of other cephalosporins. Mean terminal half-lives of 8.2 (i.m.) and 8.1 (i.v.) h obtained from this study are similar to reported values. A mean t1/20 of 6 to 9 h has been reported previously (2, 8, 9, 13) .
One Caucasian subject was included in the i.v. study. The pharmacokinetic parameters obtained were not different from those calculated with Chinese subjects.
The mean AUC values after i.m. and i.v. administration of ceftriaxone were 1,493 and 1,507 pg h/ml, respectively. Consequently, the calculated clearance was essentially identical, and a value of 1.0 was obtained for bioavailability. This suggests that a 1.0-g i.m. dose of ceftriaxone is completely absorbed. However, ceftriaxone has been shown to display nonlinear kinetics due to concentration-dependent plasma protein binding (4, 13, 14) . At plasma concentrations above 150 pug/ml, an increase in the unbound fraction of ceftriaxone together with an increase in total plasma clearance has been demonstrated (14) .
In the present study, the plasma ceftriaxone concentration did not exceed 150 ,ug/ml after i.m. administration. However, with i.v. administration plasma ceftriaxone concentrations of >150 xg/ml were observed in all subjects during the first hour of monitoring. Binding of ceftriaxone to plasma protein was not studied in this investigation. It is likely that concentration-dependent plasma protein binding of ceftriaxone also occurred in our subjects. This would result in a larger proportion of unbound ceftriaxone during the initial 1 h. Ceftriaxone is eliminated mainly by renal and biliary excretion (6) . The rate of elimination of both mechanisms is proportional to the concentration of the unbound drug. Thus, a larger fraction of ceftriaxone in the circulation would be eliminated during the first hour after i.v. administration than during any other period. This in turn would result in a smaller calculated value for the AUC after i.v. administration. Consequently, although a bioavailability of 1.0 was calculated, the actual amount of ceftriaxone absorbed might be <100% of the 1.0-g dose administered i.m.
Although the HPLC procedure used in this study has a lower detection limit of 0.5 ,ug/ml, ceftriaxone was not detected in any of the saliva samples collected. Most drugs are transported across the epithelial cell layer separating plasma and saliva mainly by passive diffusion and for some drugs by active transport (12) . Passive diffusion is governed by the concentration gradient of the non-protein-bound, lipid-soluble moiety of the drug, lipid solubility, degree of ionization, and extent of protein binding. Ceftriaxone is 95% bound to plasma protein at concentrations below 70 p,g/ml.
At 300 and 600 ,ug/ml, ceftriaxone is 84 and 58% bound to plasma protein, respectively (10, 14) . The pKa for ceftriaxone is between 2.0 and 4.5 (13, 14) . At a physiological plasma pH of 7.4, ceftriaxone exists predominantly in the ionized state. Thus, passive diffusion is unlikely to be important for transport of ceftriaxone into saliva. That ceftriaxone was not detected in any saliva samples from this study suggests that active transport for ceftriaxone is also unlikely.
In summary, this study demonstrates that the pharmacokinetic parameters obtained from healthy Chinese subjects are very similar to those previously described for healthy European or North American subjects. Thus, it may be concluded that no major modification in the established dosing regimen is required when ceftriaxone is used to treat Chinese patients.
